Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03786926 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
A Phase 1 study, sponsored by Hutchmed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT03786926 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 53 participants.
The verdict
NCT03786926, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
Interventions
- DRUG HMPL-689
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03786926
The ClinicalTrials.gov registry entry for NCT03786926 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HMPL-689 is the first listed.
NCT03786926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03786926 about?
NCT03786926 is a clinical study titled "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas". An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
What is the current status of trial NCT03786926?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2019-08-26. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT03786926?
The interventions under investigation include: HMPL-689 (DRUG).
Who is sponsoring clinical trial NCT03786926?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.